Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) CFO Sells 25,000 Shares of Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 25,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the transaction, the chief financial officer owned 8,223 shares in the company, valued at approximately $247,758.99. This trade represents a 75.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Capricor Therapeutics Stock Performance

CAPR traded up $1.50 during midday trading on Thursday, hitting $31.62. The company had a trading volume of 346,173 shares, compared to its average volume of 1,371,751. Capricor Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $40.37. The company has a market capitalization of $1.82 billion, a PE ratio of -13.99 and a beta of 0.48. The firm’s 50-day simple moving average is $27.04 and its 200-day simple moving average is $18.74.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). As a group, sell-side analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Capricor Therapeutics by 16.1% in the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after purchasing an additional 355,161 shares during the period. Suvretta Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth $51,533,000. Tang Capital Management LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at about $49,062,000. RA Capital Management L.P. bought a new stake in Capricor Therapeutics in the fourth quarter valued at about $43,516,000. Finally, Geode Capital Management LLC lifted its stake in Capricor Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock valued at $29,367,000 after buying an additional 55,766 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the company an “overweight” rating in a research report on Friday, March 13th. Piper Sandler reaffirmed an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Oppenheimer lifted their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Finally, iA Financial set a $48.00 price objective on Capricor Therapeutics in a report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.09.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.